Embecta (EMBC) Stock Price, News & Analysis

Company Overview

Embecta Corp (NASDAQ: EMBC) is a pure-play diabetes care company that was spun off from Becton, Dickinson and Company on July 1, 2021. Headquartered in Franklin Lakes, New Jersey, Embecta focuses exclusively on the development, manufacturing and commercialization of products that enable insulin delivery and blood glucose monitoring for people with diabetes.

The company’s product portfolio includes insulin infusion sets, durable and patch pumps, pen needles, infusion tubing, blood glucose test strips, lancets and lancing devices. These products are designed to support patients across the spectrum of diabetes management, from intensive insulin therapy to routine self-testing and continuous glucose monitoring systems.

Embecta serves customers in more than 100 countries through a network of direct and indirect distribution channels that include hospitals, clinics, retail pharmacies and e-commerce platforms. The company maintains a global footprint with manufacturing and distribution sites strategically located across North America, Europe and the Asia-Pacific region to ensure supply continuity and responsiveness to regional regulatory requirements.

Embecta is led by President and Chief Executive Officer Anthony J. Parker, whose leadership team leverages deep expertise in medical technology to drive innovation and expand the company’s product pipeline. Going forward, Embecta aims to enhance patient outcomes by advancing next-generation insulin delivery systems and digital health integrations that support personalized diabetes management.

Key Stats

• Today's Range: $13.67 to $13.93
• 50-Day Range: $9.79 to $15.31
• 52-Week Range: $9.20 to $21.48
• Volume: 214,640 shs
• Average Volume: 586,081 shs
• Market Capitalization: $805.88 million
• P/E Ratio: 9.62
• Dividend Yield: 4.35%
• Price Target: $19.00
• Consensus Rating: Moderate Buy

Embecta Stock Analysis - MarketRank™

Embecta scored higher than 96% of companies evaluated by MarketBeat, and ranked 42nd out of 942 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 4.1 / 5
• Analyst Rating: Moderate Buy

Consensus Rating

Embecta has received a consensus rating of Moderate Buy. The company's average rating score is 2.60, and is based on 1 buy rating, 3 hold ratings, and no sell ratings.

Upside Potential

Embecta has a consensus price target of $19.00, representing about 37.8% upside from its current price of $13.79.

Amount of Analyst Coverage

Embecta has only been the subject of 4 research reports in the past 90 days.

Earnings and Valuation

• Score: 3.8 / 5
• Proj. Earnings Growth: 7.72%

Earnings Growth

Earnings for Embecta are expected to grow by 7.72% in the coming year, from $2.85 to $3.07 per share.

Price to Earnings Ratio vs. the Market

The P/E ratio of Embecta is 9.64, which means that it is trading at a less expensive P/E ratio than the market average P/E ratio of about 234.08.

Price to Earnings Ratio vs. Sector

The P/E ratio of Embecta is 9.64, which means that it is trading at a less expensive P/E ratio than the Medical sector average P/E ratio of about 85.72.

Price to Earnings Growth Ratio

Embecta has a PEG Ratio of 0.79. PEG Ratios below 1 indicate that a company could be undervalued.

Short Interest

• Score: 4.0 / 5
• Short Interest Level: Healthy

Percentage of Shares Shorted

4.84% of the float of Embecta has been sold short.

Short Interest Ratio / Days to Cover

Embecta has a short interest ratio ("days to cover") of 4.3.

Change versus previous month

Short interest in Embecta has recently decreased by 12.33%, indicating that investor sentiment is improving significantly.

Dividend

• Score: 3.3 / 5
• Dividend Strength: Strong

Dividend Leadership

Embecta is a leading dividend payer. It pays a dividend yield of 4.23%, putting its dividend yield in the top 25% of dividend-paying stocks.

Dividend Growth

Embecta does not have a long track record of dividend growth.

Dividend Coverage

The dividend payout ratio of Embecta is 41.96%. This payout ratio is at a healthy, sustainable level, below 75%.

Dividend Sustainability

Based on earnings estimates, Embecta will have a dividend payout ratio of 19.54% next year. This indicates that Embecta will be able to sustain or increase its dividend.

Sustainability and ESG

• Score: N/A
• Environmental Score: N/A

Percentage of Shares Shorted

4.84% of the float of Embecta has been sold short.

Short Interest Ratio / Days to Cover

Embecta has a short interest ratio ("days to cover") of 4.3.

Change versus previous month

Short interest in Embecta has recently decreased by 12.33%, indicating that investor sentiment is improving significantly.

News and Social Media

• Score: 2.9 / 5
• News Sentiment: N/A

News Sentiment

Embecta has a news sentiment score of 1.28. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.56 average news sentiment score of Medical companies.

News Coverage This Week

MarketBeat has tracked 1 news article for Embecta this week, compared to 4 articles on an average week.

Search Interest

Only 1 people have searched for EMBC on MarketBeat in the last 30 days. This is a decrease of 0% compared to the previous 30 days.

MarketBeat Follows

4 people have added Embecta to their MarketBeat watchlist in the last 30 days. This is an increase of 300% compared to the previous 30 days.

Company Ownership

• Score: 1.7 / 5
• Insider Trading: N/A

Insider Buying vs. Insider Selling

In the past three months, Embecta insiders have not sold or bought any company stock.

Percentage Held by Insiders

Only 0.42% of the stock of Embecta is held by insiders.

Percentage Held by Institutions

93.83% of the stock of Embecta is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

EMBC Stock Analysis - Frequently Asked Questions

How have EMBC shares performed this year?

Embecta's stock was trading at $20.65 at the beginning of the year. Since then, EMBC shares have decreased by 33.2% and is now trading at $13.7850.

How were Embecta's earnings last quarter?

Embecta Corp. (NASDAQ:EMBC) released its earnings results on Friday, August, 8th. The company reported $1.12 earnings per share for the quarter, beating analysts' consensus estimates of $0.77 by $0.35. Embecta's revenue for the quarter was up 8.4% on a year-over-year basis.
Read the conference call transcript.

How do I buy shares of Embecta?

Shares of EMBC stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

What other stocks do shareholders of Embecta own?

Based on aggregate information from My MarketBeat watchlists, some other companies that Embecta investors own include Waste Connections (WCN), AU Optronics (AUOTY), The RMR Group (RMR), DiamondRock Hospitality (DRH), American Water Works (AWK), iShares Micro-Cap ETF (IWC) and Triple Flag Precious Metals (TFPM).

Company Calendar

• Last Earnings: 8/08/2025
• Record date for 9/15 Dividend: 8/29/2025
• Ex-Dividend for 9/15 Dividend: 8/29/2025
• Dividend Payable: 9/15/2025
• Today: 10/08/2025
• Next Earnings (Estimated): 11/25/2025
• Fiscal Year End: 9/30/2026

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Medical
• Industry: Medical Services
• Sub-Industry: Medical Equipment
• Current Symbol: NASDAQ:EMBC
• CIK: 1872789
• Web: www.embecta.com
• Phone: 201-847-6880
• Fax: N/A
• Employees: 2,100
• Year Founded: N/A

Price Target and Rating

• Average Price Target for Embecta: $19.00
• High Price Target: $25.00
• Low Price Target: $12.00
• Potential Upside/Downside: +37.9%
• Consensus Rating: Moderate Buy
• Rating Score (0-4): 2.60
• Research Coverage: 5 Analysts

Profitability

• EPS (Trailing Twelve Months): $1.43
• Trailing P/E Ratio: 9.64
• Forward P/E Ratio: 4.84
• P/E Growth: 0.79
• Net Income: $78.30 million
• Net Margins: 7.58%
• Pretax Margin: 9.10%
• Return on Equity: -23.40%
• Return on Assets: 14.46%

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: 2.47
• Quick Ratio: 1.78

Sales & Book Value

• Annual Sales: $1.12 billion
• Price / Sales: 0.72
• Cash Flow: $3.24 per share
• Price / Cash Flow: 4.25
• Book Value: ($12.80) per share
• Price / Book: -1.08

Miscellaneous

• Outstanding Shares: 58,490,000
• Free Float: 58,239,000
• Market Cap: $805.99 million
• Optionable: Optionable
• Beta: 1.10